Jade Biosciences, Inc.
NASDAQ: JBIO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Tom Frohlich
- Employees
- 50
- Headquarters
- Waltham, United States
- IPO year
- 2025
- Market cap
- $714.5M
- Website
- https://jadebiosciences.com
Loading JBIO…
Loading profile data…Frequently asked questions about JBIO
What does Jade Biosciences, Inc. (JBIO) do?
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobuli...
Where does JBIO trade?
Jade Biosciences, Inc. (JBIO) trades on the NASDAQ Global Market.
What sector is JBIO in?
Jade Biosciences, Inc. (JBIO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Jade Biosciences, Inc.?
Tom Frohlich is the chief executive officer of Jade Biosciences, Inc. (JBIO).
Where is Jade Biosciences, Inc. headquartered?
Jade Biosciences, Inc. is headquartered in United States.
Does JBIO pay a dividend?
Yes — Jade Biosciences, Inc. (JBIO) paid a trailing twelve-month dividend of USD 2.40 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did JBIO go public?
Jade Biosciences, Inc. (JBIO) completed its initial public offering in 2025.